Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada.
Department of Critical Care, Scarborough Health Network, Scarborough, ON, Canada.
Can J Anaesth. 2023 Jul;70(7):1226-1233. doi: 10.1007/s12630-023-02501-7. Epub 2023 Jun 6.
Descriptive information on referral patterns and short-term outcomes of patients with respiratory failure declined for extracorporeal membrane oxygenation (ECMO) is lacking.
We conducted a prospective single-centre observational cohort study of ECMO referrals to Toronto General Hospital (receiving hospital) for severe respiratory failure (COVID-19 and non-COVID-19), between 1 December 2019 and 30 November 2020. Data related to the referral, the referral decision, and reasons for refusal were collected. Reasons for refusal were grouped into three mutually exclusive categories selected a priori: "too sick now," "too sick before," and "not sick enough." In declined referrals, referring physicians were surveyed to collect patient outcome on day 7 after the referral. The primary study endpoints were referral outcome (accepted/declined) and patient outcome (alive/deceased).
A total of 193 referrals were included; 73% were declined for transfer. Referral outcome was influenced by age (odds ratio [OR], 0.97; 95% confidence interval [CI], 0.95 to 0.96; P < 0.01) and involvement of other members of the ECMO team in the discussion (OR, 4.42; 95% CI, 1.28 to 15.2; P < 0.01). Patient outcomes were missing in 46 (24%) referrals (inability to locate the referring physician or the referring physician being unable to recall the outcome). Using available data (95 declined and 52 accepted referrals; n = 147), survival to day 7 was 49% for declined referrals (35% for patients deemed "too sick now," 53% for "too sick before," 100% for "not sick enough," and 50% for reason for refusal not reported) and 98% for transferred patients. Sensitivity analysis setting missing outcomes to directional extreme values retained robustness of survival probabilities.
Nearly half of the patients declined for ECMO consideration were alive on day 7. More information on patient trajectory and long-term outcomes in declined referrals is needed to refine selection criteria.
对于因呼吸衰竭而接受体外膜肺氧合(ECMO)治疗的患者,其转院模式和短期预后的描述性信息尚不清楚。
我们进行了一项前瞻性单中心观察性队列研究,纳入了 2019 年 12 月 1 日至 2020 年 11 月 30 日期间因严重呼吸衰竭(COVID-19 和非 COVID-19)转诊至多伦多总医院(接收医院)的 ECMO 患者。收集了与转诊、转诊决策和拒绝原因相关的数据。拒绝原因被分为三个互斥类别,这些类别是事先选择的:“现在病得太重”、“之前病得太重”和“病得不够重”。在被拒绝的转诊中,调查了转诊医生,以收集转诊后第 7 天的患者结局。主要研究终点是转诊结局(接受/拒绝)和患者结局(存活/死亡)。
共纳入 193 例转诊,其中 73%因转院被拒绝。转诊结局受到年龄(比值比[OR],0.97;95%置信区间[CI],0.95 至 0.96;P < 0.01)和 ECMO 团队其他成员参与讨论(OR,4.42;95%CI,1.28 至 15.2;P < 0.01)的影响。在 46 例(24%)转诊中,患者结局缺失(无法联系到转诊医生或转诊医生无法回忆起结局)。使用可用数据(95 例拒绝和 52 例接受转诊;n = 147),拒绝转诊患者在第 7 天的存活率为 49%(“现在病得太重”的患者存活率为 35%,“之前病得太重”的患者存活率为 53%,“病得不够重”的患者存活率为 100%,未报告拒绝原因的患者存活率为 50%),而接受转诊患者的存活率为 98%。将缺失结局设定为定向极端值的敏感性分析保留了生存概率的稳健性。
近一半因 ECMO 考虑而被拒绝的患者在第 7 天仍然存活。需要更多关于拒绝转诊患者的患者轨迹和长期结局的信息,以完善选择标准。